Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Isis Earns $2.15M Biogen Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News

Isis Earns $2.15M Biogen Milestone

Advances Phase III study evaluating ISIS-SMNRx in children with SMA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals has earned a $2.15 million milestone payment from Biogen for advancing the ongoing Phase III study (CHERISH) evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). To date, Isis has received more than $120 million in payments from Biogen related to the development of ISIS-SMNRx.
 
The Phase III study of ISIS-SMNRx, will evaluate the efficacy and safety of 12 mg doses of ISIS-SMNRx with a primary endpoint of a change in the Hammersmith Functional Motor Scale-Expanded (HFMSE), a validated method to measure changes in muscle function in patients with SMA.     
 
SMA is a severe genetic disease for which there are no approved treatments. The disease is caused by a loss of, or defect in, the survival motor neuron 1 (SMN1) gene, which is critical for the health and survival of nerve cells in the spinal cord that are responsible for neuromuscular growth and function. 
 
Isis and Biogen have a broad strategic alliance focused on leveraging antisense technology to advance the treatment of neurological and neuromuscular disorders.  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics